Utah People's Post

The Latest News from the Beehive State

Tuesday, January 19, 2021
Log in
  • National News
    • Female Caseworker Killed & Doctor Shot in Philadelphia
  • State News
    • Car Chase Leads to Drug Arrest
  • Tech & Science
  • Health
    • How to Prepare For Ticks Season
    • Magical Weight Loss Bean Scam
  • Sports
  • Business
You are here: Home / Health / First Results for the Ebola Vaccine Show Promise

First Results for the Ebola Vaccine Show Promise

Posted by

First Results for the Ebola Vaccine Show PromiseThe Ebola vaccine that scientists have been struggling to come up with in the battle against the fatal disease has just undergone the first testing phase and proves amazing potential.

So far, the Ebola outbreak in West Africa has caused nearly 16,000 cases of infection, and 5,674 deaths over the territory of the three countries most affected by it – Liberia, Sierra Leone and Guinea. Given the dire state of the situation, researchers from the National Institute of Allergy and Infectious Disease have developed a new vaccine that has been labeled as a potential breakthrough after the first tests. The candidate is currently known as cAd3-EBO and it is one of the two developed vaccines currently subjected to testing.

cAd3-EBO uses a replication-defective recombinant to deliver the glycoprotein from 2 species of Ebola virus and has been tested on 20 volunteers. All hosts of the vaccine have responded to the treatment positively, receiving antibody response in a short period of time. The second phase of the test consisted of observing the way different doses of the vaccine reacted in the body. Higher doses not only induced greater response, but also stimulated T-cell activity from the immune system on the patients, enhancing the body’s ability to protect itself from contagion. Out of the 20 cases put under observation, there have been no records of side effects for the lower-dose volunteers, while two of the targets that received higher doses presented temporary fever.

At this point, this is the only possible way to combat the disease, with no known cures available for already infected individuals. Scientists from the National Institute of Allergy and Infectious Disease (NIAID) are working in collaboration with the drug-making company GlaxoSmithKline (GSK) to further develop the vaccine, with a focus on a monovalent version that will target the Zaire protein only, in hopes of speeding up the process of putting an end to the current outbreak which involves the Zaire strain of the virus.

Naturally the trials currently being run on the Ebola vaccine are of a far too small scale to be able to give forth a definite answer. The testing phase will have to extend on a much wider range of subjects before it can be declared viable and safe. Meanwhile, the 60-60-70 goal that was set by the World Health Organization in October is still in effect, but medical workers present at the scene are showing some difficulty at keeping up with the set targets. Ebola response teams in the affected countries are eagerly awaiting a positive result from the researchers.

Share this:

  • Tweet
  • Share on Tumblr
  • Email

Filed Under: Health Tagged With: cAd3-EBO, Ebola, Ebola cure, Ebola outbreak, ebola vaccine, Ebola virus, NIAID

Woman working out at the gym

Just 23% of Americans Are Working Out Enough in Their Spare Time

By

Poliovirus Therapy Gives Brain Cancer Patients New Hope (Study)

By

United Airlines airplane

Passenger Mysteriously Dies on United Airlines flight Bound for Boston

By

Breakfast sandwich

Here Are Some Foods No Nutritionist Would Ever Eat

By

Poppy flower

UN Warns of Surge in Opium-based Drugs and Cocaine Supply

By

U.S.-Canada border

French Jogger Detained 2 Weeks for Accidentally Crossing Border

By

Plus size model

Normalizing Plus Size Could Fuel Obesity Crisis (Study)

By

Giant manta ray

Unique Manta Ray Nursery Spotted off Texas Coast

By

The rainbow flag

WHO Scraps Transgenderism from List of Mental Illnesses

By

456 People Dead at U.K. Hospital after Taking too Many Painkillers

By

Kenyan girls dancing

Kenyans Facing Poor Nutrition as Supermarket Shopping Is on the Rise

By

Pages

  • About
  • Contact
  • Privacy Policy GDPR
  • Staff
  • Terms and Conditions

Recent Posts

  • Just 23% of Americans Are Working Out Enough in Their Spare Time
  • Poliovirus Therapy Gives Brain Cancer Patients New Hope (Study)
  • Passenger Mysteriously Dies on United Airlines flight Bound for Boston
  • Here Are Some Foods No Nutritionist Would Ever Eat
  • UN Warns of Surge in Opium-based Drugs and Cocaine Supply
  • French Jogger Detained 2 Weeks for Accidentally Crossing Border
  • Normalizing Plus Size Could Fuel Obesity Crisis (Study)

Related Articles

  • Woman working out at the gym

    Just 23% of Americans Are Working Out Enough in Their Spare Time

  • Poliovirus Therapy Gives Brain Cancer Patients New Hope (Study)

  • Breakfast sandwich

    Here Are Some Foods No Nutritionist Would Ever Eat

  • Normalizing Plus Size Could Fuel Obesity Crisis (Study)

  • The rainbow flag

    WHO Scraps Transgenderism from List of Mental Illnesses

  • 456 People Dead at U.K. Hospital after Taking too Many Painkillers

  • Young woman affected by depression

    If You Have PTSD You Were Likely Abused as a Child

  • Obese dog on a leash

    Obese Dogs Can Help Us Better Understand How Obesity Works

  • Our Brains Are Craving Combinations of Fats and Carbs (Study)

  • Hungry bird with beck open

    Scientists Explain Why We Get ‘Hangry’

Categories

  • Business
  • Entertainment
  • Health
  • National News
  • Nature
  • Provo
  • Salt Lake News
  • Science
  • Sports
  • State News
  • Tech & Science
  • Technology
  • Uncategorized
  • West Jordan
  • West Valley City
  • World

Copyright © 2021 utahpeoplespost.com

About · Privacy Policy · Terms of Use · Site Map · Contact

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This website uses cookies to ensure you get the best experience on our website. Learn more.